Chronic Myeloid Leukemia (CML)

- IRB 10537: Ph 1, oral ABL001 for CML or Ph+ ALL
  - Chronic and Accelerated phase, Ph+
  - Relapsed/ Refractory or intolerant to TKI

- IRB 15085: Ph 2, ponatinib for CP-CML
  - Chronic Phase
  - Resistant to at least two prior TKI

Key:
- Open for Enrollment
- In Development
- Enrollment on Hold

1/4/2017

www.ohsu.edu/cancer